Geron Corporation to Present at Biotechnology Industry Organization Investor Forum
Posted on: Tuesday, 9 October 2007, 09:00 CDT
Geron Corporation (Nasdaq:GERN) today announced that Alan B. Colowick, Ph.D., M.P.H., president, oncology, will present an update of the company's oncology programs at 10:45 a.m. PDT on Wednesday, Oct. 10, 2007, at the Biotechnology Industry Organization Investor Forum in San Francisco.
The update will cover information about Geron's portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1).
The audio and slide presentation will be available at the following website address: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GERN&item_id= 1657780. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) The replay will be available 24 hours after the live presentation and will be archived for 30 days.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
Source: Business Wire
Related Articles
- Geron Receives Milestone Payment From Merck Triggered By IND Filing for Telomerase Cancer Vaccine Candidate
- Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
- MaxCyte Technology Licensed for Use in Geron's Cancer Vaccines
- Geron Presents Data On HIV/AIDS Drug Candidate at the XVI International AIDS Conference
- Geron Corporation Reports 2006 First Quarter Financial Results
- Geron Corporation Reports Fourth Quarter and Annual 2005 Financial Results and Events
- Geron Licenses MaxCyte Cell Loading Technology for Use in Closed-System Cancer Vaccine Manufacturing
- Geron and Cambrex Announce Contract Manufacturing Arrangement for cGMP Production of GRNVAC1 for Clinical Trials
- Geron Corporation Reports 2005 Third Quarter Financial Results and Events
- Geron Announces Publications Demonstrating Efficacy of GRN163L, Its Pan-Cancer Drug, in Animal Models of Human Liver and Lung Cancer
 |
 |
User Comments (0)
RSS Feeds